Week 6 Exam: NR565 / NR 565
(Latest ) Advanced
Pharmacology Fundamentals |
Questions & Answers | 100%
Correct | Grade A - Chamberlain
Question:
Beclomethasone (QVAR)
Answer:
· Inhaled corticosteroid - anti-inflammatory
· For long term control of airway inflammation in clients with asthma and
COPD. Daily use to prevent acute exacerbations
· Long term use can cause bone cause, cataracts and glaucoma In high
doses
· First line treatment for persistent asthma. Minimal side effects compared
to oral.
,Question:
Phosphodiesterase-4 Inhibitor MOA
Answer:
· Roflumilast, oral anti-inflammatory medication approved for sever chronic
COPD exacerbation or prophylaxis as add on to bronchodilators.
· Direcly modulates inflammatory process in lung tissue
· Selectively inhibits phosphodiesterase (PDE), raising the levels of cyclic
adenosine monophosphate (cAMP).
· Raised levels of cAMP in lungs reduces inflammation by suppressing
cytokine release and decreasing pulmonary infiltration by neutrophils and
other WBC's.
· Suppresses cough and mucous production. Improves mucociliary
clearance
Question:
COPD Management Goals
Answer:
· First goal: Reduce symptoms, improve patient's health status, increase
exercise tolerance
· Second goal: reduce risk of mortality. Completed through preventing
COPD progression and preventing and managing exacerbations.
· Completed through bronchodilators, glucocorticoids, PDE4 inhibitos.
, Question:
Tiotropium (Spiriva)
Answer:
· Long acting anticholingeric drug
· Handinhaler DPI
For COPD
Question:
Adverse Effects of LAMAs
Answer:
· Long acting muscarinic antagonist inhaler
· Dry mouth, urinary retention, constipation and diarrhea, headache,
blurred vision, cough, paradoxical broncho spasm, increased risk of
pneumonia
(Latest ) Advanced
Pharmacology Fundamentals |
Questions & Answers | 100%
Correct | Grade A - Chamberlain
Question:
Beclomethasone (QVAR)
Answer:
· Inhaled corticosteroid - anti-inflammatory
· For long term control of airway inflammation in clients with asthma and
COPD. Daily use to prevent acute exacerbations
· Long term use can cause bone cause, cataracts and glaucoma In high
doses
· First line treatment for persistent asthma. Minimal side effects compared
to oral.
,Question:
Phosphodiesterase-4 Inhibitor MOA
Answer:
· Roflumilast, oral anti-inflammatory medication approved for sever chronic
COPD exacerbation or prophylaxis as add on to bronchodilators.
· Direcly modulates inflammatory process in lung tissue
· Selectively inhibits phosphodiesterase (PDE), raising the levels of cyclic
adenosine monophosphate (cAMP).
· Raised levels of cAMP in lungs reduces inflammation by suppressing
cytokine release and decreasing pulmonary infiltration by neutrophils and
other WBC's.
· Suppresses cough and mucous production. Improves mucociliary
clearance
Question:
COPD Management Goals
Answer:
· First goal: Reduce symptoms, improve patient's health status, increase
exercise tolerance
· Second goal: reduce risk of mortality. Completed through preventing
COPD progression and preventing and managing exacerbations.
· Completed through bronchodilators, glucocorticoids, PDE4 inhibitos.
, Question:
Tiotropium (Spiriva)
Answer:
· Long acting anticholingeric drug
· Handinhaler DPI
For COPD
Question:
Adverse Effects of LAMAs
Answer:
· Long acting muscarinic antagonist inhaler
· Dry mouth, urinary retention, constipation and diarrhea, headache,
blurred vision, cough, paradoxical broncho spasm, increased risk of
pneumonia
